[Multiple sclerosis--recent advances in pathogenesis and treatment].
Itoyama
Yasuto
Y
Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Sendai 980-8574, Japan.
Fujihara
Kazuo
K
Nakashima
Ichiro
I
Misu
Takeo
T
Fujimori
Toshikazu
T
Sato
Shigeru
S
D015551:Autoimmunity; D001379:Azathioprine / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000209:etiology* / Q000235:genetics / Q000628:therapy*; D018992:Myelin-Associated Glycoprotein / Q000502:physiology; D009188:Myelitis, Transverse / Q000503:physiopathology; D009902:Optic Neuritis / Q000503:physiopathology; D010455:Peptides / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018992:Myelin-Associated Glycoprotein; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D001379:Azathioprine; D000068556:Interferon beta-1a